IDENTIFYING THE BENLYSTA PATIENT

WHICH OF YOUR PATIENTS COULD BENEFIT FROM BENLYSTA?

  • Diagnosis of lupus or lupus nephritis
  • Experiencing active disease

START BENLYSTA NOW TO HELP PATIENTS LIKE:

* Hypothetical patient profiles. May not be representative of all BENLYSTA patients.

Lindsay*

A patient with lupus

  • SEE DETAILS

    • 37 years old
    • Diagnosed with SLE 3 years ago

    Current medications

    • Hydroxychloroquine 300 mg/day – 3 years
    • Prednisone 7.5 mg/day

    Lab values and physical exam

    • Positive antinuclear antibodies (ANA)
    • ESR 30 mm/hr
    • Anti-dsDNA elevated
    • Swelling in joints of hands, knees, and ankles

    anti-dsDNA = anti-double-stranded DNA; ESR = erythrocyte sedimentation rate; SLE = systemic lupus erythematosus.

Valerie*

A patient with lupus and organ damage

  • SEE DETAILS

    In an SLE clinical trial in Black patients, efficacy response rates were higher with BENLYSTA vs placebo. The improvement was not statistically significant and the safety profile of BENLYSTA was consistent with the overall population.

    • 30 years old
    • Diagnosed with SLE 7 years ago
    • Currently has active lupus with an SDI score
      of 1

    Current medications

    • Hydroxychloroquine 400 mg/day – 2 years
    • MMF not tolerated
    • Prednisone 10 mg/day

    Lab values and physical exam

    • Scarring alopecia (SDI score = 1)
    • Osteoporosis
    • Arthritis

    MMF = mycophenolate mofetil; SDI = SLICC/ACR Damage Index; SLE = systemic lupus erythematosus.

    Approximately 1 in 2 patients experience permanent organ damage within 5 years of diagnosis.1,2

Ashley*

A patient recently diagnosed with lupus nephritis

  • SEE DETAILS

    Did you know that BENLYSTA can be used in patients with lupus nephritis?

    • 34 years old
    • Diagnosed with SLE 4 years ago
    • Recently diagnosed with lupus nephritis

    SLE therapy

    • Hydroxychloroquine 300 mg/day
    • Prednisone 15 mg/day for 4 months, tapered to 5 mg/day

    ~2 months ago, presented with the following:

    • Proteinuria 2.4 g/24 hours
    • Active urinary sediment
    • Renal biopsy confirmed Class III lupus nephritis

    Induction therapy

    • CYC 500 mg IV, every 2 weeks
    • 3 IV pulses of methylprednisolone 750 mg/pulse
      • Followed by oral prednisone 1 mg/kg/day

    CYC = cyclophosphamide; IV = intravenous; SLE = systemic lupus erythematosus.

Sophia*

A pediatric patient with lupus

  • SEE DETAILS

    Did you know that BENLYSTA IV can be used in patients with SLE as young as 5 years old?3

    • 12 years old
    • Diagnosed with SLE 2 years ago

    Current medications

    • Hydroxychloroquine 200 mg/day – 2 years
    • Prednisone 7.5 mg/day – 2 years

    Current lab values

    • Positive antinuclear antibodies (ANA) ≥1:80
    • Proteinuria ≥0.5 mg/24 hours

    Current disease activity score

    • SELENA-SLEDAI = 9

    SELENA SLEDAI = Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index; SLE = systemic lupus erythematosus.

Ready to prescribe BENLYSTA to one of your patients?

GET STARTED

USEFUL TOOLS FOR YOUR PRACTICE

Here are some tools to help you assess your patients' lupus
and help you provide them with the best treatment option.

SELENA-SLEDAI PDF

A tool to assess disease activity in patients with SLE

Download

SLICC/ACR Damage Index

A tool to assess organ damage in patients with SLE

Download

SELENA-SLEDAI TOOL

A tool to calculate a patient's score

VIEW TOOL

Start BENLYSTA now for your appropriate patients